#USA #Plano #Onkos Surgical #NanoCept #ELEOS System

Onkos Surgical Achieves 500th NanoCept® Case Using the ELEOS™ Limb Salvage System

Onkos Surgical, known for its cutting-edge solutions in musculoskeletal oncology, has marked a significant achievement with the completion of its 500th case involving the NanoCept® Antibacterial Technology integrated into the ELEOS™ Limb Salvage System. This milestone, announced on June 29, 2026, underscores the increasing adoption of advanced antibacterial implant technologies in the challenging realm of complex orthopaedic procedures.

The journey of the NanoCept technology began with its De Novo authorization received in 2024. Since then, it has gained traction among surgeons involved in intricate orthopaedic oncology and revision scenarios, where the threat of bacterial contamination is a critical concern. The technology aims to reduce bacterial presence on implant surfaces prior to their insertion, providing an extra layer of protection for patients undergoing surgery.

The landmark procedure took place in Plano, Texas, under the expert hands of Dr. Cyrus Abbaschian. He expressed the profound significance of reaching this milestone, stating, "Reaching the 500th NanoCept case is a meaningful milestone, not just for the technology, but for the patients we treat. In complex orthopaedic oncology and revision procedures, every step we take to help mitigate bacterial contamination matters. Having NanoCept integrated into the ELEOS system provides a sophisticated tool for successfully managing these cases."

The ELEOS Limb Salvage System is specially designed to support orthopaedic surgeons facing the difficulties of significant bone loss and reconstruction challenges. With the integration of NanoCept technology, surgeons have more options to combat bacterial risks as part of a comprehensive intraoperative strategy. Patrick Treacy, Founder and CEO of Onkos Surgical, commented on this achievement, saying, "The completion of our 500th NanoCept case with the ELEOS system reflects the growing adoption of this technology among surgeons treating some of the most complex orthopaedic conditions. Since our De Novo authorization, our focus has been on expanding access to NanoCept in a thoughtful, evidence-driven way."

The milestone not only celebrates the number of cases but also highlights the recent advancements within the NanoCept platform, which has seen expanded availability across more components and materials of the ELEOS system. This progress aligns with Onkos Surgical’s commitment to delivering integrated and innovative solutions tailored for musculoskeletal oncology and complex orthopaedic conditions.

As a leader in providing innovative solutions for complex orthopaedic challenges, Onkos Surgical is dedicated to enhancing surgeons' capabilities in addressing patient-specific clinical complications. The company's solutions, ranging from antibacterial implant coatings to 3D anatomical models and tailored workflow optimization, empower over 350 leading academic medical institutions across the United States to make informed decisions in complex revision and oncological cases. Although the efficacy of NanoCept technology in preventing or reducing infection rates remains to be fully established in human clinical trials, the pathway forged by Onkos serves as a hopeful indication of the future of surgical interventions in orthopaedics.

For more information about Onkos Surgical and its array of products and services, visit www.onkossurgical.com.

Disclaimer

Forward-looking statements made in this release are subject to known and unknown risks which could materially affect actual outcomes compared to those expressed or implied. Management believes that these expectations, while reasonable, should not be deemed guarantees of future results. The company assumes no obligation to update any forward-looking statements unless required by law.